FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2162287242> ?p ?o ?g. }

• W2162287242 endingPage "4592" @default.
• W2162287242 startingPage "4587" @default.
• W2162287242 abstract "To determine a biweekly dose of oxaliplatin for combination with full-dose gemcitabine and concurrent radiation therapy (RT) in pancreatic cancer.Patients with previously untreated pancreatic cancer received gemcitabine days 1, 8, and 15, and oxaliplatin days 1 and 15, repeated at 28-day intervals. RT (27 Gy in 1.8-Gy fractions) was administered during cycle 1. Dose escalation was guided using the time-to-event continuous reassessment method. Dose levels 1 to 4 included gemcitabine 1 g/m2 intravenously (IV) during 30 minutes and oxaliplatin 40, 55, 70, or 85 mg/m2 IV during 90 minutes, respectively; for dose levels 5 and 6, oxaliplatin dose remained 85 mg/m2 but infusion time for gemcitabine 1 g/m2 was increased to 65 or 100 minutes, respectively. The trial objective was to determine the dose level associated with dose-limiting toxicity (DLT) through cycle 2 in < or = 20% of patients.Forty-four patients were enrolled (median age, 64 years; 27 men, 17 women) with resectable (n = 12), unresectable (n = 29), and metastatic (n = 3) pancreatic cancer. Ten DLTs occurred in nine patients, including grade 4 platelets (n = 4), decline in performance status (n = 2), GI bleeding (n = 2), and GI toxicity (n = 2). The estimated probability of DLT for dose level 3 was .21 (90% posterior probability interval [PI], .12 to .33); for dose level 4, the estimated probability was .24 (90% PI, .14 to .36).The addition of oxaliplatin 85 mg/m2 days 1 and 15 to full-dose gemcitabine and radiation therapy was well tolerated. On the basis of these results, a multi-institutional neoadjuvant phase II study in resectable pancreatic cancer is planned." @default.
• W2162287242 created "2016-06-24" @default.
• W2162287242 creator A5011163683 @default.
• W2162287242 creator A5011595369 @default.
• W2162287242 creator A5024695793 @default.
• W2162287242 creator A5030459924 @default.
• W2162287242 creator A5046132413 @default.
• W2162287242 creator A5052209029 @default.
• W2162287242 creator A5061377078 @default.
• W2162287242 creator A5066378306 @default.
• W2162287242 creator A5082916383 @default.
• W2162287242 creator A5085891308 @default.
• W2162287242 date "2007-10-10" @default.
• W2162287242 modified "2023-10-01" @default.
• W2162287242 title "Phase I Study of Oxaliplatin, Full-Dose Gemcitabine, and Concurrent Radiation Therapy in Pancreatic Cancer" @default.
• W2162287242 cites W1892409143 @default.
• W2162287242 cites W1931508686 @default.
• W2162287242 cites W1940632416 @default.
• W2162287242 cites W2002483815 @default.
• W2162287242 cites W2003032215 @default.
• W2162287242 cites W2006750936 @default.
• W2162287242 cites W2018678771 @default.
• W2162287242 cites W2022848495 @default.
• W2162287242 cites W2041465871 @default.
• W2162287242 cites W2047318784 @default.
• W2162287242 cites W2061274398 @default.
• W2162287242 cites W2062278291 @default.
• W2162287242 cites W2077003423 @default.
• W2162287242 cites W2079934168 @default.
• W2162287242 cites W2083513265 @default.
• W2162287242 cites W2097642908 @default.
• W2162287242 cites W2101465269 @default.
• W2162287242 cites W2129197203 @default.
• W2162287242 cites W2129204015 @default.
• W2162287242 cites W2139248078 @default.
• W2162287242 cites W2146266646 @default.
• W2162287242 cites W2150405633 @default.
• W2162287242 cites W2158134441 @default.
• W2162287242 cites W2167228337 @default.
• W2162287242 cites W2241000821 @default.
• W2162287242 cites W3011957479 @default.
• W2162287242 cites W4244014048 @default.
• W2162287242 cites W4297819854 @default.
• W2162287242 doi "https://doi.org/10.1200/jco.2007.12.0592" @default.
• W2162287242 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/17925553" @default.
• W2162287242 hasPublicationYear "2007" @default.
• W2162287242 type Work @default.
• W2162287242 sameAs 2162287242 @default.
• W2162287242 citedByCount "51" @default.
• W2162287242 countsByYear W21622872422012 @default.
• W2162287242 countsByYear W21622872422013 @default.
• W2162287242 countsByYear W21622872422014 @default.
• W2162287242 countsByYear W21622872422015 @default.
• W2162287242 countsByYear W21622872422016 @default.
• W2162287242 countsByYear W21622872422017 @default.
• W2162287242 countsByYear W21622872422018 @default.
• W2162287242 countsByYear W21622872422020 @default.
• W2162287242 countsByYear W21622872422021 @default.
• W2162287242 countsByYear W21622872422022 @default.
• W2162287242 crossrefType "journal-article" @default.
• W2162287242 hasAuthorship W2162287242A5011163683 @default.
• W2162287242 hasAuthorship W2162287242A5011595369 @default.
• W2162287242 hasAuthorship W2162287242A5024695793 @default.
• W2162287242 hasAuthorship W2162287242A5030459924 @default.
• W2162287242 hasAuthorship W2162287242A5046132413 @default.
• W2162287242 hasAuthorship W2162287242A5052209029 @default.
• W2162287242 hasAuthorship W2162287242A5061377078 @default.
• W2162287242 hasAuthorship W2162287242A5066378306 @default.
• W2162287242 hasAuthorship W2162287242A5082916383 @default.
• W2162287242 hasAuthorship W2162287242A5085891308 @default.
• W2162287242 hasBestOaLocation W21622872421 @default.
• W2162287242 hasConcept C121608353 @default.
• W2162287242 hasConcept C126322002 @default.
• W2162287242 hasConcept C126894567 @default.
• W2162287242 hasConcept C2780210213 @default.
• W2162287242 hasConcept C2780258809 @default.
• W2162287242 hasConcept C2780962732 @default.
• W2162287242 hasConcept C29730261 @default.
• W2162287242 hasConcept C2989005 @default.
• W2162287242 hasConcept C509974204 @default.
• W2162287242 hasConcept C526805850 @default.
• W2162287242 hasConcept C71924100 @default.
• W2162287242 hasConcept C90924648 @default.
• W2162287242 hasConceptScore W2162287242C121608353 @default.
• W2162287242 hasConceptScore W2162287242C126322002 @default.
• W2162287242 hasConceptScore W2162287242C126894567 @default.
• W2162287242 hasConceptScore W2162287242C2780210213 @default.
• W2162287242 hasConceptScore W2162287242C2780258809 @default.
• W2162287242 hasConceptScore W2162287242C2780962732 @default.
• W2162287242 hasConceptScore W2162287242C29730261 @default.
• W2162287242 hasConceptScore W2162287242C2989005 @default.
• W2162287242 hasConceptScore W2162287242C509974204 @default.
• W2162287242 hasConceptScore W2162287242C526805850 @default.
• W2162287242 hasConceptScore W2162287242C71924100 @default.
• W2162287242 hasConceptScore W2162287242C90924648 @default.
• W2162287242 hasIssue "29" @default.
• W2162287242 hasLocation W21622872421 @default.
• W2162287242 hasLocation W21622872422 @default.

• next